{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-070425","form_type":"8-K","ticker":"CHRN","cik":"0001549084","company_name":"EKSO BIONICS HOLDINGS, INC.","filed_at":"2023-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.344793+00:00","generated_at":"2026-06-14T02:55:54.646604+00:00","sec_items":["1.01","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Ekso Bionics removes $6.75 floor from ATM offering; shareholders approve share plan increase","bullets":["Amended at-the-market offering agreement with H.C. Wainwright to remove $6.75 per share floor, effective June 12, 2023.","Prior ATM sales: 77,594 shares at avg $10.72 for $791,217 net proceeds; $6.67M remains available.","Shareholders approved 2014 Equity Incentive Plan amendment, increasing authorized shares from 2,524,286 to 3,724,286.","All five director nominees elected; advisory say-on-pay passed with ~4.1M For vs 293K Against.","Ratified WithumSmith+Brown as independent auditor for FY2023 with ~7.0M For votes."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-070425","json":"https://secwatch.observer/filing/0001104659-23-070425.json","markdown":"https://secwatch.observer/filing/0001104659-23-070425.md","text":"https://secwatch.observer/filing/0001104659-23-070425.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549084/000110465923070425/0001104659-23-070425-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549084/000110465923070425/tm2318337d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T02:55:54.646604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84e83dc6f2e96d90168f5a2312a3ed773c9631f5","claim":"EKSO BIONICS HOLDINGS, INC. amended Amendment with H.C. Wainwright & Co., LLC (effective 2023-06-12).","evidence_excerpt":"On June 12, 2023, Ekso Bionics Holdings, Inc. (the “Company”) entered into an amendment (the “Amendment”) to that certain At the Market Offering Agreement dated as of October 9, 2020 (the “Sales Agreement”), by and between the Company and H.C. Wainwright & Co., LLC (the “Agent”), pursuant to which the Company may offer and sell, from time to time, through the Agent, shares of the Company’s common stock, par value $0.001 per share (the “Shares”), in an “at-the-market” offering.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549084/000110465923070425/0001104659-23-070425-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"},{"label":"Effective","value":"2023-06-12"}],"fact_type":"material_agreement"},{"claim_id":"93084f50b81b728d8880dde419be2d39f4dba46b","claim":"EKSO BIONICS HOLDINGS, INC. shareholders approved Ratification of appointment of WithumSmith+Brown, PC as independent auditors at the 2023-06-08 meeting.","evidence_excerpt":"For Against Abstained Broker Non-votes 7,027,946 152,140 49,764 n/a","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549084/000110465923070425/0001104659-23-070425-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"},{"claim_id":"c91b1c145e15f215ebad504ad43338f54bd8d173","claim":"EKSO BIONICS HOLDINGS, INC. shareholders approved Amendment of 2014 Equity Incentive Plan to increase authorized shares from 2,524,286 to 3,724,286 at the 2023-06-08 meeting.","evidence_excerpt":"For Against Abstained Broker Non-votes 3,898,757 551,457 22,272 2,757,364","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549084/000110465923070425/0001104659-23-070425-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"},{"claim_id":"dce13d0ca0a229125d55d76aca8d83501951925a","claim":"EKSO BIONICS HOLDINGS, INC. shareholders approved Advisory vote on named executive officer compensation at the 2023-06-08 meeting.","evidence_excerpt":"For Against Abstained Broker Non-votes 4,111,482 293,055 67,949 2,757,364","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549084/000110465923070425/0001104659-23-070425-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"},{"claim_id":"ed435bec7c177ec3e7764a6a8502d56c9fc100d5","claim":"EKSO BIONICS HOLDINGS, INC. shareholders approved Election of five persons to the Company’s board of directors at the 2023-06-08 meeting.","evidence_excerpt":"Scott G. Davis 4,312,949 159,537 2,757,364","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549084/000110465923070425/0001104659-23-070425-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}